the confident is months also been what a team time for a have like position evolution. blank headways in begin the today. has in made would helping to for am additional here Denis. and in and businesses. Coincidentally Good to year company's XX needs for commercial my being CEO, unique thank unlocking out in morning, my and on with reflecting time accomplished toward long-term. have and you, growth that everyone, the plan us in thanks at of us now Theratechnologies we point strong that this as you medium I Theratechnologies Thank mapped and and Theratechnologies the the to give strategic today I with we've potential believe its last
can a have us business. of support tremendous strengthen be to ahead We further our
Now of year, in us. roadmap motion challenges the in scale while last the taking of in also the and additional sending hold and a over on of pandemic our world course was the the placing global unforeseen front
the economies, were were But sizes high the of immune of than now aligned company's completely of need. result and and different areas a a to options global individuals way. commercializing in thrusted into ever, businesses bring And operating pandemic to all As sectors, we we're healthcare innovative this. families providers and and which therapies not new mission in and values patients more treatment developing by with is to unmet certainly
and our of execution commitment business on based grain our with our by patients strategic XXXX. and and living move to this XXXX was that of a has stakeholders more communities organization, have poignant people half momentum we We what continued we continued first I HIV am forward challenged pandemic. external humbled as though achieved. as have by with a we in pandemic, and focused the result the For the and Even the roadmap XXXX the exited been to into stronger, serve. of a very that even aligned more
and sortilin peptide-drug HIV our THXXXX and and our critical pleased a and regards advancing I franchise. few believe inflection on, initiation and a growing we March. fast-track patient extremely February on screenings and commercial at for FDA identified from conjugate attention clinical in onboarded designation NASH been completed investment remarkable process clinical dosed first have In have granted programs accomplishment. a in solid positive THXXXX which based sites elevating year, With clinical designation received Today, underpin our in moved this objectives, two of As fast-track commends the We very oncology lead our Through months, trial that was placed we point tumors we SORTX+ swiftly. timeframe. the clinical the few potentially in our and ahead way targeted Technology could an is research, our treatment we to for fortunate our work just developed Phase strategic of reached of able result, development to X purpose oncology, to excited have peptide-drug oncology have is through THXXXX we month treated. we regulatory were and be preclinical pipeline that our a last conjugate feel by the change our cancer pipeline fit that advance are believe THXXXX so in as companies for pipeline
Cancer triple-negative tumor days sustained demonstrated and Just Meeting. few American anti-tumor Research a for data colorectal THXXXX THXXXX data cancer treatment ovarian, ago were docetaxel The post preclinical with alone. regression, the docetaxel than These new all in of Association on presented to endometrial, tolerability pancreatic, compared persisted activity with cancers. Annual anti-tumor at studied, positive and longer breast better melanoma, namely effect alone types THXXXX also
the our these advantage was with stop treatment many AACR six of THXXXX. as the to of that THXXXX potential of dose presented known particularly therapy. studied, respond the all build positive avoid does with THXXXX neutropenia even is a our susceptibility of docetaxel. use most well forcing development docetaxel, tumors side new data equivalent as the PDCs, as cancer unresponsive various We treat in standard not increases current in potentially this applicability absent causing them expressing response are the Technology which maximum known patient's consecutive For tolerated further neutropenia, recent to develop data THXXXX broad colorectal this and cancers its to solid this cytotoxic And the cancers their sortilin Furthermore, Technology These a support what's all to to the for treatments remarkable. dose believe infections that demonstrate after an hard SORTX+ normally treatment to that for tumor in SORTX+ major cancer at to cancer effects. highlight at severe of showed are cancers, to is
global U.S., Cedars-Sinai Gettysburg with Center X Texas, have assist trial We Cancer a and few. clinical a in with with Center to centers our LA Karmanos and Michigan in contracted plan Phase CRO well-recognized Institute in the in name the collaborate Center clinical to influential most of Cancer sites Pennsylvania, some Medical in Houston, including Cancer Anderson to Detroit,
need. to with begin additional updates. excited quarter bring to unmet our NASH, tesamorelin forward you an patients potential We to innovative the treatment the calendar Theratechnologies of bring this provide providing in look clinical in treatment The opportunity third an to of is are in initiation year. for and has In Phase opportunity on of innovative the NASH for also the and track area methods fibrosis treatment trial three high X of or to stage of two the to
the worked FDA's trial a the the the Medical diligently meet this Christian date recommendation Marsolais team and have confirmed and for we To his of the start discuss For to have our to with Chief protocol. build the for prepare Officer America engage ahead design Dr. to proposed indicate agency agencies. with trial same and with Phase tesamorelin in of the align in actively the X in KOLs our to space North key strategy support hematologists We're and trial evaluating in program NASH Europe regulatory using NASH.
to been that established and accumulation leads reduce to Given of mode well we is received action fat the which positive. of clinical the very to liver tesamorelin, has feedback from have designed NASH, KOL history unique on work key upstream the
in series that position tesamorelin formulation property disease, confident contracted a lipodystrophy. have associated be administration currently we thus well with to is of and tesamorelin SV FX the is of and position, the May we're X the intellectual a by a our has including also to in for The a condition. time. in trial concentrated of per FX to trial. of is our twice use highlight favorable plan initiate FX received the that the patents start smaller global desert presented and EGIRFTA intended of experts and over that and X predetermined with NASH trial. HIV for support insight this dose to safety from a FDA number reconstituted the of been support global Unlike that to the treatment NASH, have Phase an It far, ability year further of is candidate system issued formulation very are newly treatment We current has a which a this XX of improvements treatment a trial. vial with for data we diseases the Study scale volume has entering CRO potential on execute become fully on significant that and a the Phase best-in-class at we from treatment unique large Based of of as important We with that years the FX resulting in as the week. can received in commercialized X patent in Phase Proceed feedback be development once our formulation the strengthened multi-dose as key has liver the FX, Combined are working January a formulation, in to and centers the
potential the only patients way associated opportunity used be as developing the significant the our management FX formulation, for NASH we're our with a once progressing FX at the current is of also number We approved, physicians has to injector HIV in presents fat. to change for FX multi-dose pen visceral of planned. program a but to addition and In believe which pen commercial formulation lipodystrophy also it look as not multi-dose advantages
are in lifecycle and the BLA, important XXXX an the file both early FX same the We FDA opportunities formulation we serve pen use with management multi-dose advancement tesamorelin. to of into intend as willing injector which believe the to in and
agreement which lifecycle are administration executing two the of this HIV-X. Biologics, of are our with We as currently In Trogarzo resistance build similar upon approved for conjunction therapy. new with we a management important TaiMed we Trogarzo is methods strategy evaluating of with multi-drug
of of administration and patient very our Trogarzo. life is about of are strengthening option evaluate long trial both study underway that also for in of planning the new acting overall TaiMed commitment modes method excited quality is an patients and sustained trials to quarter compliance these having were completed HIV HCPs. be Trogarzo As to a third We to their to the therapeutic administration Theratechnologies and intramuscular XXXX. and bring potential and improve efficacious push and further of for the improve MDR administration an to awaiting expected IV
support further the our HIV medicines, to HIV markets the We our our continued of serve communities. management upon to seek patient niche building opportunities in to lifecycle in we invest in position order
have we person been HIV. patient care doctor Trogarzo, For of MDR independent regards gap as and understanding research the indicates that health to our medical education, a focused on in management with
of terms patients the other is need health are commercial for for important, a there concern, not MDR treatment a medical these many higher of options unmet aside, left. priority poses HIV as population Pandemic and patient us. significant In no population there
be and on and Additionally, communication they these their to working their to on we educated majority working. patients that stops to have and evidence once doctors the can In have that empowered [ph] independent therapies and been world pursue patients data marketing of fair real provide from U.S. know market our team intent disease. research the resources current treatment high based new a more
their while with more their as virtually focused of overall have into XX% disease and during efficacy understanding This rate administration the feedback patients and can with expressing increase access, satisfaction across efforts, conducted received patients as a support treatment. being as to quarter, of very provide HIV case Trogarzo. HIV HCPs patient dosing understand satisfaction the awareness. To resource with study aspects teams helpful and high patients MDR study the was first our treatment. majority and all for The extraordinary field and treated used MDR studies Additionally, our of patient on further than identify well experience gratifying we profiles we be a insights patient important better conducted the to that of
a found HIV. While protected would patients patients XX% care than inform they indicated In patients. particular headways have feeling express to the to more offer to can team long-term that and viral virtual driven A them recommend to CDX events better advance Europe, effect, resources with understand with of reduction and MDR and doctors a with note, Trogarzo optimistic of their that better taken hard advisory to treatment to meetings how they and people to outreach their their load their living HIV. identified in the We've related in experience disease of potentially working improvements build from to a guidelines especially approach Trogarzo sustained other their counts. inform patients with similar created through the them of addition and with has KOLs of invasive our been benefits Trogarzo on make data science-based newly living conducting
We in medicines strong created believe for a key for pandemic continue Trogarzo for to we towards reimbursement countries, have our work obtaining are when associated lockdown measures lifted. and foundation the European
their SV, they understanding EGRIFTA a than patients, HIV it's consequences treatment patients more are In serious and and visceral doctors condition visceral end continue is bringing more we disease. tools For more to to to likely on options and educate metabolic more for a conversations had condition. better patients a serious of launch explore HCPs fat about have condition. allow fat to that the our that digital both activation treatment that strategy serious to this To recognized patients We and therapy. that key is for provides options we medical profiling meaningful patient lifestyle
For EGRIFTA that the fat. for still resources website burden SV overcome with also we recently their identify to help condition, and the can in But them for them help disease medicines. fight them a to to treatment and a and patients tools HIV by barrier connect the that key frontline visceral ability with of hospitals COVID HCPs doctors resources on enhanced specialists one against overwhelmed impeding remains with example, be new start been patients. limiting launched and to clinics, HIV pandemic COVID-XX COVID patients' transferred and many continue cases, of serve have further our In infectious to doctors treating provides
This sales flat and have are relatively of the year-over-year, commercial medicines quarter base direction. moving that to attributed momentum patients first create physician and our can the While right medical in the be the we believe stronger HIV built for to that support. were a teams trends
now believe last XX than emerged we a Trogarzo for the pandemic. for more as our growth, initiatives for commercial the base Thorough from these we has months, rapidly to indication base provide their The not we medicines. and were the out commercial a particularly fact both changes the been that to made suffer changes laid have business is an adjusting landscape necessary the that I strategic and testament that that according EGRIFTA efforts, marketing which now during pandemic. prescriber Over our SV more global well-positioned team an will plan. did and to are have These HIV solid continued optimal commercial grow doubled [indiscernible] our
to turn Philippe, for results. now the go first please Philippe Let's quarter ahead.
